secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0000950170-23-036440
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla reports Q2 2023 net loss of $35.8M; cash $168.7M funds into 2025
------------------------------------------------------------------------

- Net loss of $35.8M for Q2 2023 vs $28.9M in Q2 2022; R&D expenses rose to $31.0M from $20.7M.
- Cash at June 30, 2023 was $168.7M, down from $215.5M at Dec 31, 2022; expected to fund operations into 2025.
- Phase 2 potentially registrational BA3011 UPS study continues enrolling; FDA meeting request submitted for NSCLC study.
- CAB-CTLA-4 BA3071 cleared fifth cohort (5 mg/kg) with no DLTs; sixth cohort enrolling; Phase 1 data readout on track for 2H23.
- Anticipated data across BA3021 NSCLC, melanoma, SCCHN to enable 'go' decision for indications in 2H23.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000095017023036440/0000950170-23-036440-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000095017023036440/bcab-20230801.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-036440

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer